Primary angioplasty with 2nd generation drug-eluting stents

Original title: Stent thrombosis with second-generation drug-eluting stents compared with bare-metal stents: Network meta-analysis of primary percutaneous coronary intervention trials in ST-segment–elevation myocardial infarction. Reference: Circ Cardiovasc Interv. 2013; Epub ahead of print.

To compare the safety and efficacy of 2nd generation drug-eluting stents (DES) versus bare metal stents (BMS) in the context of primary angioplasty was conducted this meta-analysis that included 21 works with all types of stents (1st  generation DES, 2nd  generation DES and BMS) for this indication. In total, these 21 studies totaled 12866 patients with 2 jobs who provided direct evidence (2nd generation DES versus BMS) and 19 jobs with indirect evidence (15 comparing 1st generation DES versus BMS and 4 comparing 1st generation DES versus 2nd generation). Both at 30 days (OR 0.36, CI 95% 0.15 to 0.82) and one year (OR 0.49, CI 95%, 0.30 to 0.79) stent thrombosis incidence was significantly lower with 2nd generation DES compared with BMS. Similar to thrombosis, re-infarction (OR 0.3, CI 95%, 0.17 to 0.54) and revascularization (OR 0.54, CI 95%, 0.80 to 0.98) were also lower at one year with 2nd generation DES. Mortality in contrast, showed no significant differences both, after 30 days as well as one year between the 2 devices.

Conclusion:

This meta-analysis of randomized trials in primary angioplasty showed a lower incidence of stent thrombosis, myocardial infarction and target vessel revascularization with 2nd generation drug-eluting stents compared with conventional stents. 

Editorial comment

This study has methodological limitations; basically the only direct evidence comes from 2 studies with the remainder of the proxy data. It was also a limitation, considering the fact within the 2nd generation DES those with permanent polymer and bio-absorbable polymer that maybe could have different safety and efficacy (although the evidence available in the NEXT trial suggests otherwise).

SOLACI.ORG

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...